BRAF and ovarian carcinoma: Neratinib significantly enhanced valproate lethality in multiple tumor cell types, including PDX models of mutant B-RAF melanoma, glioblastoma and ovarian cancer, in colon and pancreatic cancer, and in the afatinib resistant H1975 clones (Figure 2C; Table 1 ; Supplementary Figure 2).